Abstract

We investigated the adhesive behavior of mesenchymal stem cells (MSC) in blood, which might influence their fate when infused as therapy. Isolated human bone marrow MSC (BMMSC) or umbilical cord MSC (UCMSC) adhered efficiently from flow to the matrix proteins, collagen, or fibronectin, but did not adhere to endothelial selectins. However, when suspended in blood, BMMSC no longer adhered to collagen, while UCMSC adhered along with many aggregated platelets. Neither MSC adhered to fibronectin from flowing blood, although the fibronectin surface did become coated with a platelet monolayer. UCMSC induced platelet aggregation in platelet rich plasma, and caused a marked drop in platelet count when mixed with whole human or mouse blood in vitro, or when infused into mice. In contrast, BMMSC did not activate platelets or induce changes in platelet count. Interestingly, isolated UCMSC and BMMSC both adhered to predeposited platelets. The differences in behavior in blood were attributable to expression of podoplanin (an activating ligand for the platelet receptor CLEC‐2), which was detected on UCMSC, but not BMMSC. Thus, platelets were activated when bound to UCMSC, but not BMMSC. Platelet aggregation by UCMSC was inhibited by recombinant soluble CLEC‐2, and UCMSC did not cause a reduction in platelet count when mixed with blood from mice deficient in CLEC‐2. We predict that both MSC would carry platelets in the blood, but their interaction with vascular endothelium would depend on podoplanin‐induced activation of the bound platelets. Such interactions with platelets might target MSC to damaged tissue, but could also be thrombotic. Stem Cells 2018;36:1062–1074

Highlights

  • Mesenchymal stem cells (MSC) are multipotent stem-like cells extracted first from the bone marrow (BM), but recently obtained from umbilical cords (UCs) and adipose tissue [1]

  • The differences in behavior in blood were attributable to expression of podoplanin, which was detected on umbilical cord MSC (UCMSC), but not bone marrow MSC (BMMSC)

  • Platelet aggregation by UCMSC was inhibited by recombinant soluble CLEC-2, and UCMSC did not cause a reduction in platelet count when mixed with blood from mice deficient in CLEC-2

Read more

Summary

Introduction

Mesenchymal stem cells (MSC) are multipotent stem-like cells extracted first from the bone marrow (BM), but recently obtained from umbilical cords (UCs) and adipose tissue [1]. MSC have the ability to repair damaged tissue [2]. Administration of bone-marrow mesenchymal stem cells (BMMSC) improved the outcome in animal models of chronic cardiac ischemia and acute myocardial infarction [3,4,5]. Immunosuppressive effects of MSC include induction of apoptosis of activated T cells [8], expansion of immunosuppressive Tregs [9, 10], suppression of monocyte differentiation into dendritic cells [11], and cross-talk with endothelial cells to downregulate recruitment of leukocytes [8]. MSC have been widely used in clinical trials, in which they are commonly

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call